Sulfuric Acid

Sulfuric Acid

SCHEMBL48929

O=S(=O)(O)O.O=c1ccc2ccccc2[nH]1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.80
CA9 Q16790 5/20 0.80
CA1 P00915 1/20 0.80
CA3 P07451 1/20 0.80
CA4 P22748 1/20 0.80
CA6 P23280 1/20 0.80
CA5A P35218 1/20 0.80
CA7 P43166 1/20 0.80
CA13 Q8N1Q1 1/20 0.80
CA14 Q9ULX7 1/20 0.80
CA5B Q9Y2D0 1/20 0.80
ALDH1A1 P00352 2/20 0.45
DAO P14920 2/20 0.44
F11 P03951 1/20 0.44
DDO Q99489 1/20 0.44
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
PKM P14618 1/20 0.43
AKR1B1 P15121 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL31503134 1.00 CA12 (0.80) CA12CA9CA1CA3CA4
SCHEMBL28110424 0.92 CA12 (0.74) CA12CA9CA1CA3CA4
SCHEMBL5437282 0.89 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL29351086 0.89 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL30958273 0.89 CA12 (1.00) CA12CA9CA1CA3CA4
SCHEMBL8621 0.89 CA12 (1.00) CA12CA9CA1CA3CA4
Trifluoromethanesulfonic Acid SCHEMBL2480378 0.88 CA12 (0.67) CA12CA9CA1CA3CA4
Methyl Alcohol SCHEMBL10568722 0.88 CA12 (0.87) CA12CA9CA1CA3CA4
Water SCHEMBL10661261 0.87 CA12 (0.95) CA12CA9CA1CA3CA4
Hydrochloric Acid SCHEMBL1824447 0.87 CA12 (0.95) CA12CA9CA1CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615053-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS Temple Otorongo LLC (US) 2020-03-04 EP claimed
CN-110191876-A FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE 奥巴斯治疗股份有限公司 2019-08-30 CN claimed
EP-3523274-A1 FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE Orbus Therapeutics, Inc. (US) 2019-08-14 EP claimed
WO-2018200381-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS TEMPLE OTORONGO LLC (US) 2018-11-01 WO claimed
WO-2018148206-A1 TREATMENT OF DIABETES AND ASSOCIATED METABOLIC CONDITIONS WITH EPIGENETIC MODULATORS TEMPLE OTORONGO LLC (US) 2018-08-16 WO claimed
WO-2018067401-A1 FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE Orbus Therapeutics, Inc. (US) 2018-04-12 WO claimed
EP-2797569-B1 AQUEOUS OXIDIZING COMPOSITION KAO GERMANY GMBH (DE) 2017-10-25 EP claimed
EP-3205334-A1 METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA Santen Pharmaceutical Co., Ltd. (JP) 2017-08-16 EP claimed
EP-2772249-B1 Method and composition for treating ocular hypertension and glaucoma SANTEN PHARMACEUTICAL CO LTD (JP) 2017-05-03 EP claimed
US-9573909-B2 6-acyl-1,2,4-triazine-3,5-dione derivative and herbicides FMC CORPORATION (US) 2017-02-21 US claimed
US-20020177624-A1 Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis BLANSETT PHARMACAL COMPANY, INC. 2002-11-28 US claimed
EP-1133985-A1 PRESSURE-SENSITIVE ADHESIVE GEL COMPOSITION FOR IONTOPHORESIS AND APPARATUS THEREFOR HISAMITSU PHARMACEUTICAL CO. INC. (JP) 2001-09-19 EP claimed
WO-2001060337-A1 COMPOSITIONS FOR TOPICAL DELIVERY OF A PHARMACEUTICALLY ACTIVE AGENT HAVING REDUCED OXIDATION THE PROCTER & GAMBLE COMPANY (US) 2001-08-23 WO claimed
EP-0126684-B1 DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS MERCK & CO. INC. (US) 1991-08-28 EP claimed
EP-0148242-A4 METHOD AND APPARATUS FOR TREATING AILMENTS. KRAUSER ROBERT S 1987-06-03 EP claimed
EP-0148242-A1 METHOD AND APPARATUS FOR TREATING AILMENTS. KRAUSER ROBERT S 1985-07-17 EP claimed
US-4523589-A INHALATION THROUGH NASAL PASSAGES VIRAL RESPONSE SYSTEMS, INC., A DE. CORP. 1985-06-18 US claimed
WO-1985000112-A1 METHOD AND APPARATUS FOR TREATING AILMENTS KRAUSER ROBERT S 1985-01-17 WO claimed
EP-0126684-A2 Drug delivery system utilizing thermosetting gels MERCK & CO. INC. (US) 1984-11-28 EP claimed
US-4478822-A Drug delivery system utilizing thermosetting gels MERCK & CO., INC. (US) 1984-10-23 US claimed